Study details
Enrolling now
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Milton S. Hershey Medical Center
NCT IDNCT06482853ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
52
Study length
about 4.2 years
Ages
18–65
Locations
1 site in PA
What this study is about
Researchers are testing a treatment called angiotensin-(1-7) to see if it can improve cardiovascular health in people with obesity and high blood pressure. The trial will last for 1528 days, and the goal is to enroll 52 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Angiotensin-(1-7)
- 2.Take Saline
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
angiotensin II
Endpoints
Secondary: Change in Diastolic Blood Pressure, Change in Heart Rate, Change in Systolic Blood Pressure
Body systems
Endocrinology, Cardiology / Heart